Results 21 to 30 of about 35,575 (190)

Serum micrornas as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma [PDF]

, 2016
The diagnosis of primary sclerosing cholangitis (PSC) is difficult due to the lack of sensitive and specific biomarkers, as is the early diagnosis of cholangiocarcinoma (CC), a complication of PSC.
Alpini, Gianfranco, Alvaro, Domenico, Bernuzzi, Francesca, Bowlus, Christopher L, Carbone, Marco, Eric Gershwin, M, He, Xiao Song, Invernizzi, Pietro, Lleo, Ana, Locati, Massimo, Marabita, Francesco, Marzioni, Marco, Mirolo, Massimiliano, Muri Boberg, Kirsten, Piscaglia, Fabio, Rimassa, Lorenza, Torzilli, Guido, Yang, Guo Xiang   +17 more
core   +2 more sources

CAQ Corner: Immune‐mediated complications

, 2022
Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley   +1 more source

Multitrait genome-wide analyses identify new susceptibility loci and candidate drugs to primary sclerosing cholangitis

Nature Communications, 2023
The genetic basis of primary sclerosing cholangitis has only been partially uncovered. Here, the authors perform a multitrait genome-wide association study to provide insight into the genetic etiology of primary sclerosing cholangitis risk and possible ...
Younghun Han, Jinyoung Byun, Catherine Zhu, Ryan Sun, Julia Y. Roh, Heather J. Cordell, Hyun-Sung Lee, Vikram R. Shaw, Sung Wook Kang, Javad Razjouyan, Matthew A. Cooley, Manal M. Hassan, Katherine A. Siminovitch, Trine Folseraas, David Ellinghaus, Annika Bergquist, Simon M. Rushbrook, Andre Franke, Tom H. Karlsen, Konstantinos N. Lazaridis, The International PSC Study Group, Katherine A. McGlynn, Lewis R. Roberts, Christopher I. Amos   +23 more
doaj   +1 more source

Clinical Features and Risk Factors of Autoimmune Liver Involvement in Pediatric Inflammatory Bowel Disease [PDF]

, 2016
OBJECTIVES:Autoimmune liver disease is reported in up to 7.8% of children with inflammatory bowel disease. A distinct inflammatory bowel disease phenotype has been suggested in adults and in small pediatric cohorts.
Alexopoulou, Alvarez, Block, Boonstra, Deneau, Dotson, Faubion, Feldstein, Goyal, Gregorio, Halliday, Hirschfield, Hov, Jose, Jose, Levine, Levine, Liberal, Loftus, Loftus, Lundqvist, Maggiore, Malaty, Mieli-Vergani, Navaneethan, Noble-Jamieson, Olsson, Ordonez, Penna, Rönnblom, Sokol, Zholudev   +31 more
core   +1 more source

Postoperative association between impaired renal function and vascular dysfunction in liver transplant recipients

, 2022
Liver Transplantation, EarlyView.
Domenico A. Chavez, Marie‐Claire Evans, Natalie J. Bohmke, Hiba Kamal, Loan Quynh Tran, Chandra Bhati, Susan Wolver, Mohammad S. Siddiqui, Danielle L. Kirkman   +8 more
wiley   +1 more source

Pembrolizumab Induced Sclerosing Cholangitis: Why You Need a Liver Biopsy

Case Reports in Oncology, 2023
The advent of checkpoint inhibitor immunotherapy has rapidly changed the landscape of the management of cancers. However, its use has also been associated with the rise of immunotherapy-related adverse effects (irAEs).
Ian Liang, Geoffrey Chu, Robert Zielinski   +2 more
doaj   +1 more source

Rapid Progression of Primary Sclerosing Cholangitis Complicated with Ulcerative Colitis

Case Reports in Gastrointestinal Medicine, 2015
Primary sclerosing cholangitis is a cholestatic condition with unknown etiology and long-standing, progressive course, leading to cirrhosis and requiring orthotropic liver transplant. In approximately 80%, primary sclerosing cholangitis is accompanied by
Piotr Pardak, Ewa Walczak, Rafał S. Filip   +2 more
doaj   +1 more source

Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up

BMJ Open Gastroenterology, 2020
Nivolumab is an immune checkpoint inhibitor used to treat multiple solid-organ malignancies. While many of its immune-related adverse events are well established, nivolumab-induced sclerosing cholangitis remains poorly characterised, with no defined ...
Wanyuan Cui, Tess McClure, Khashayar Asadi, Thomas John, Adam Testro   +4 more
doaj   +1 more source

Primary Sclerosing Cholangitis and Sarcoidosis. Case Report and Review of the Literature

Canadian Journal of Gastroenterology, 1990
A 43-year-old man with longstanding ulcerative colitis developed primary sclerosing cholangitis established by cholangiography and liver biopsy. Within one year of the diagnosis of primary sclerosing cholangitis, pulmonary sarcoidosis developed, proven ...
Gerry N Schep, Linda J Scully
doaj   +1 more source

REMEDI: REinforcement learning-driven adaptive MEtabolism modeling of primary sclerosing cholangitis DIsease progression [PDF]

arXiv, 2023
Primary sclerosing cholangitis (PSC) is a rare disease wherein altered bile acid metabolism contributes to sustained liver injury. This paper introduces REMEDI, a framework that captures bile acid dynamics and the body's adaptive response during PSC progression that can assist in exploring treatments.
arxiv